Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 3.387 billion yuan for 2025, representing a year-on-year growth of 13.56%. The net profit attributable to the parent company was 372 million yuan, up 19.20% year-on-year, while the net profit excluding non-recurring items was 298 million yuan, an increase of 8.33% [3][4] - In Q4 2025, the company achieved a revenue of 990 million yuan, marking a year-on-year growth of 34.79%, with a net profit of 111 million yuan, up 86.17% year-on-year [3][4] - The company is accelerating its merger and acquisition strategy to expand overseas channels, with overseas revenue reaching approximately 299 million yuan in 2025, a staggering growth of 405.05% year-on-year [5] - A strategic partnership with Philips has been established, granting the company brand authorization for seven product categories, which is expected to contribute to revenue growth starting in the second half of 2026 [6] Financial Performance Summary - The company expects revenues for 2026, 2027, and 2028 to be 4.132 billion yuan, 5.132 billion yuan, and 6.286 billion yuan, respectively, with growth rates of 22.0%, 24.2%, and 22.5% [8] - The net profit attributable to the parent company is projected to be 466 million yuan, 590 million yuan, and 763 million yuan for 2026, 2027, and 2028, respectively, with growth rates of 25.5%, 26.4%, and 29.3% [8] - The company's gross margin is expected to improve from 53.2% in 2025 to 55.8% in 2028 [10] - The earnings per share (EPS) is forecasted to be 2.23 yuan, 2.82 yuan, and 3.65 yuan for 2026, 2027, and 2028, respectively [10]
可孚医疗：2025年业绩符合预期，增长新动能充足-20260313